# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K192072   
B Applicant Roche Diagnostics Operations (RDO)   
C Proprietary and Established Names Tina-quant C-Reactive Protein IV   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DCN</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 866.5270C-Reactive ProteinImmunological TestSystem</td><td rowspan=1 colspan=1>IM - Immunology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New Device   
B Measurand: C-Reactive Protein (CRP)   
C Type of Test: Quantitative, immunoturbidimetric assay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below. B Indication(s) for Use:

Tina-quant $\textsuperscript { \textregistered }$ C-Reactive Protein IV is an immunoturbidimetric assay for the in vitro quantitative determination of CRP in human serum and plasma on cobas c systems.

A C-reactive protein immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the C-reactive protein in serum and plasma. Measurement of C-reactive protein aids in evaluation of the amount of injury to body tissues.

C Special Conditions for Use Statement(s): Rx – For Prescription Use Only

D Special Instrument Requirements: Cobas c 501 Analyzer

# IV Device/System Characteristics:

# A Device Description:

The Tina-quant C-Reactive Protein IV is a latex particle enhanced immunoturbidimetric assay consisting of two working reagents:

R1: TRIS buffer with bovine serum albumin (BSA) with preservatives R2: Latex particles coated with mouse anti-CRP in glycine buffer, mouse immunoglobulins with preservative.

# B Principle of Operation:

Human CRP agglutinates with latex particles coated with monoclonal anti-CRP antibodies. The precipitate is determined turbidimetrically. The assay is meant to be run on the cobas c 501.

# V Substantial Equivalence Information:

A Predicate Device Name(s): Tina-quant C-Reactive Protein Gen. 3

B Predicate 510(k) Number(s): K083444

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp;PredicateDevice(s):</td><td colspan="1" rowspan="1">New DeviceK192072</td><td colspan="1" rowspan="1">PredicateK083444</td></tr><tr><td colspan="1" rowspan="1">Device TradeName</td><td colspan="1" rowspan="1">Tina-quant C-Reactive ProteinIV</td><td colspan="1" rowspan="1">Tina-quant C-Reactive ProteinGen. 3</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicSimilarities</td><td colspan="1" rowspan="1">New DeviceK192072</td><td colspan="1" rowspan="1">Predicate DeviceK083444</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications ForUse</td><td colspan="1" rowspan="1">Tina-quant® C-Reactive ProteinIV is an immunoturbidimetricassay for the in vitro quantitative</td><td colspan="1" rowspan="1">Immunoturbidometric assay forthe in vitro quantitativedetermination of CRP in human</td></tr><tr><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">determination of CRP in humanserum and plasma on cobas csystems.A C-reactive proteinimmunological test system is adevice that consists of the reagentsused to measure byimmunochemical techniques theC-reactive protein in serum andplasma. Measurement of C-reactive protein aids in evaluationof the amount of injury to bodytissues.</td><td colspan="1" rowspan="1">serum and plasma on Rocheautomated clinical chemistryanalyzers.Measurement of C-Reactiveprotein aids in the evaluation ofthe amount of injury to bodytissues.</td></tr><tr><td colspan="1" rowspan="1">Assay Method</td><td colspan="1" rowspan="1">Particle enhancedimmunoturbidimetric assay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">DetectionMethod</td><td colspan="1" rowspan="1">Turbidimetric</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum and Plasma (Li-heparin,K2- and K3-EDTA)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Calibrator f.a.s. Proteins</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Expected Value</td><td colspan="1" rowspan="1">&lt;5 mg/L</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent Stability</td><td colspan="1" rowspan="1">Shelf-life at 28 °C: expirationdate on cobas c pack labelOn-board in use and refrigeratedon the analyzer: 12 weeks</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicDifferences</td><td colspan="1" rowspan="1">New DeviceK192072</td><td colspan="1" rowspan="1">Predicate DeviceK083444</td></tr><tr><td colspan="1" rowspan="1">Traceability/Standardization</td><td colspan="1" rowspan="1">Standardized against the ERM-DA474/IFCC</td><td colspan="1" rowspan="1">Standardized against CRM 470</td></tr><tr><td colspan="1" rowspan="1">InstrumentPlatform</td><td colspan="1" rowspan="1">cobas c 501 analyzer</td><td colspan="1" rowspan="1">Roche automated clinicalchemistry analyzers</td></tr><tr><td colspan="1" rowspan="1">CalibrationMethod</td><td colspan="1" rowspan="1">6-point spline</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">CalibrationInterval</td><td colspan="1" rowspan="1">After reagent lot changeAfter 3 weeks on-board theanalyzerAfter 6 months when using asingle reagent lotAs required following qualitycontrol procedures</td><td colspan="1" rowspan="1">After reagent lot changeAs required following qualitycontrol procedures</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">CRP T Control NPrecinorm Protein</td><td colspan="1" rowspan="1">Precinorm ProteinPrecipath Protein</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">•Precipath ProteinPreciControl ClinChem Multi 1PreciControl ClinChem Multi 2</td><td colspan="1" rowspan="1">PreciControl ClinChem Multi 1PreciControl ClinChem Multi 2</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">3.0 - 350 mg/L</td><td colspan="1" rowspan="1">0.3 - 350 mg/L</td></tr></table>

# VI Standards/Guidance Documents Referenced:

CLSI EP05-A3, Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline - Third Edition • CLSI EP6-A, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach: Approved Guideline CLSI EP17-A2, Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline – Second Edition Guidance for Industry and FDA Staff: Review Criteria for Assessment of C-Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Protein (cCRP) Assays

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

i) Precision of the Tina-quant CRP IV evaluated by testing five human serum samples and three controls with concentrations that cover the assay range. The samples were tested in two replicates per run, two runs per day for 21 days using three reagent lot on one cobas c 501 Analyzer for a total of 84 replicates per sample. The SD and $\% C V$ of the within-run, between-run, between-day, and total imprecision were calculated for each sample and results are summarized in the following table:

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(mg/L)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4.55</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>10.6</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>82.4</td><td rowspan=1 colspan=1>1.82</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.76</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>186</td><td rowspan=1 colspan=1>3.76</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.91</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.24</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>4.39</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>331</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.65</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.69</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>CRPTN*</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>PNP**</td><td rowspan=1 colspan=1>9.7</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>PPP***</td><td rowspan=1 colspan=1>55.2</td><td rowspan=1 colspan=1>0.86</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>1.9</td></tr></table>

\* CRPTN: CRP T Control N \*\* PNP: Precinorm Protein control \*\*\* PPP: Precipath Protein control

ii) Lot-to-lot imprecision:

The panel of four serum samples was tested with three different assay reagent lots. Each sample was tested in two replicates per run, two runs per day for 21 days. The lot-to-lot imprecision was evaluated based on a total of 252 measurements per sample. The results are summarized in the following table:

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(mg/L)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>4.57</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>85.9</td><td rowspan=1 colspan=1>1.85</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.84</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>3.11</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>3.71</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>Serum 4</td><td rowspan=1 colspan=1>187</td><td rowspan=1 colspan=1>3.46</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.73</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.92</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>5.63</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Serum 5</td><td rowspan=1 colspan=1>336</td><td rowspan=1 colspan=1>4.92</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.17</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>4.69</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>7.74</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>CRPTN*</td><td rowspan=1 colspan=1>3.61</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>PNP**</td><td rowspan=1 colspan=1>9.7</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>PPP***</td><td rowspan=1 colspan=1>55.9</td><td rowspan=1 colspan=1>0.94</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.33</td><td rowspan=1 colspan=1>2.4</td></tr></table>

\* CRPTN: CRP T Control N \*\* PNP: Precinorm Protein control \*\*\* PPP: Precipath Protein control

# 2. Linearity:

Linearity of the assay was evaluated following CLSI guideline EP6-A by preparing native unmodified high- and low-level human serum pools for the dilution series. The dilution series resulted in 15 levels (including the high and low concentration pools). Each diluted sample was tested in replicates of three and tested on a cobas c 501 analyzer. Regression statistics comparing the observed results (y) to expected results (x) of all samples are presented in the table below.

<table><tr><td rowspan=1 colspan=1>Dilution Range(mg/L)</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>R²</td><td rowspan=1 colspan=1>%Bias</td></tr><tr><td rowspan=1 colspan=1>1.03-351</td><td rowspan=1 colspan=1>y=1.002x-0.0169</td><td rowspan=1 colspan=1>0.99-1.01</td><td rowspan=1 colspan=1>-0.06-0.03</td><td rowspan=1 colspan=1>0.9976</td><td rowspan=1 colspan=1>-5.2%-4%</td></tr></table>

The data summarized in the table above support linearity throughout the claimed measuring range from $3 \mathrm { m g / L }$ to $3 5 0 \mathrm { m g / L }$ .

# 3. Analytical Specificity/Interference:

a) Endogenous Substance Interference:

The effect of the presence of hemoglobin, triglyceride, conjugated bilirubin, unconjugated bilirubin, albumin, immunoglobulin, and rheumatoid factor in serum samples was evaluated by testing native unmodified serum pools at two levels with CRP concertation between $5 \mathrm { - } 1 0 \mathrm { m g / L }$ and $3 5 { \mathrm { - } } 1 0 0 \ \mathrm { m g / L }$ spiked with varying levels of each interferent and analyzed in triplicate in one assay run. The percent recovery for each sample spiked with the interference substance was calculated by comparing its result to that of the corresponding reference sample spiked with an equal volume of the solvent without the interference substance. No interference was noted for samples containing up to $1 0 0 0 \mathrm { H }$ index (hemoglobin), $1 0 0 0 \mathrm { { L } }$ index (lipemia), $6 0 \mathrm { I }$ index (conjugated bilirubin, unconjugated bilirubin), $6 0 ~ \mathrm { g / L }$ albumin, $5 0 ~ \mathrm { g / L }$ Immunoglobulin, and rheumatoid factor up to $1 2 0 0 \mathrm { \ : I U / m L }$ .

b) Exogenous Substance Interference:

The same protocol used in the endogenous substance interference study was used to evaluate potentially interfering exogenous substances. No interference was noted for samples containing N-Acetylcysteine at $1 6 6 0 \mathrm { m g / L }$ , Ampicillin-Na at $1 0 0 0 ~ \mathrm { { m g / L } }$ , Ascorbic acid at $3 0 0 \mathrm { m g / L }$ , Cefoxitin at $6 6 0 0 \mathrm { m g / L }$ , Heparin at $5 0 0 0 \mathrm { I U / L }$ , Levodopa at $2 0 \mathrm { m g / L }$ , Methyldopa $+ 1 . 5$ at $2 2 . 5 ~ \mathrm { m g / L }$ , Metronidazole at $2 0 0 \mathrm { m g / L }$ , Doxycyclin at 50 $\mathrm { m g / L }$ , Acetylsalicylic acid at $1 0 0 0 \mathrm { m g / L }$ , Rifampicin at $6 0 \mathrm { m g / L }$ , Penicillamin at 24 $\mathrm { m g / L }$ , Phenylbutazone at $4 0 0 \mathrm { m g / L }$ , Cyclosporine at $5 \mathrm { m g / L }$ , Acetaminophen at $2 0 0 \mathrm { m g / L }$ , Ibuprofen at $5 0 0 \mathrm { m g / L }$ , and Theophylline at $1 0 0 ~ \mathrm { { m g / L } }$ .

Ticarcillin did not show interference up to $2 2 5 \mathrm { m g / L }$ ; however, ticarcillin did show significant interference from $3 0 0 \mathrm { m g / L ^ { - 7 5 0 \mathrm { m g / L } } }$ .

c) HAMA Interference:

The effect of the presence of elevated level of Human anti-mouse antibody (HAMA) in serum samples was evaluated by testing native unmodified serum pools at two levels with CRP concertation between $5 \mathrm { - } 1 0 \mathrm { m g / L }$ and $3 5 { \mathrm { - } } 1 0 0 ~ { \mathrm { m g / L } }$ . Each C-reactive protein sample was spiked with a serum sample containing HAMA. Samples were run in triplicate, on three lots of reagent, on one cobas c 501 analyzer. The mean concentration of the three replicates was used to calculate recovery to the known C-reactive protein concentration. No cross reactivity was noted up to $2 0 0 0 ~ \mathrm { { n g / m L } }$ for HAMA.

4. Assay Reportable Range:

The claimed measuring range is from $3 . 0 \mathrm { m g / L }$ to $3 5 0 \mathrm { m g / L }$ .

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

a) Traceability: The CRP calibrators are traceable to the reference material, ERM-DA474/IFCC.

b) Kit Stability:

Shelf-life stability: A real-time stability study were performed in accordance with CLSI EP25-A using three lots of reagent. The study was performed at each time point with five human serum samples and three controls. The real-time stability study supports 13 months unopened shelf-life stability for Tina-quant C-Reactive Protein IV Assay when stored at $2 { - } 8 ~ ^ { \circ } \mathrm { C }$ per the manufacturer’s instruction for use.

On-board stability: A real-time stability study using three lots of reagent tested at each time point with five human serum samples and three controls. The study supports the onboard stability claim of 12 weeks.

# 6. Detection Limit:

The limit of blank (LoB), limit of detection (LoD), and limit of quantitation (LoQ) of the Tina-quant CRP IV assay on the cobas c 501 were determined according to CLSI guideline EP17-A2.

LoB was determined by testing 10 analyte free samples in singlicate per run, two runs per day, for three days on one cobas c 501 analyzer using three lots of reagents. The LoB was estimated as the $\mathrm { \dot { 9 } 5 ^ { t h } }$ percentile of 60 measurements for each of the lots tested.

LoD was determined using five serum samples with low CRP concentrations. Each sample was tested in duplicates per run, two runs per day, for three days on one cobas c 501 analyzer using three lots of reagents. The LoD was determined for each lot based on 60 measurements as the lowest amount of analyte in a concentration level that can be detected with a $9 5 \%$ probability.

LoQ was determined using a set of nine samples with low CRP concentrations. Each sample was tested in replicates of five per run, one run per day, for five days with three reagent lots on one cobas c 501 analyzer for a total of 25 data points per sample per reagent lot. The LoQ is defined as the mean value of the sample which fulfills the specification for the total withinlaboratory imprecision $< 2 0 \%$ CV.

The claimed LoB, LoD and LoQ for the Tina-Quant are summarized in the table below:   

<table><tr><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoQ</td></tr><tr><td rowspan=1 colspan=1>Tina-Quant CRP IV</td><td rowspan=1 colspan=1>0.2 mg/L</td><td rowspan=1 colspan=1>0.3 mg/L</td><td rowspan=1 colspan=1>3.0 mg/L</td></tr></table>

The claimed lower limit of the analytical reportable range for Tina-Quant CRP IV is set to be $3 \mathrm { m g / L }$ .

# 7. Assay Cut-Off:

Not applicable

# B Comparison Studies:

1. Method Comparison with Predicate Device:

A total of 110 native serum samples spanning the measuring range were tested with the Tinaquant C-Reactive Protein IV and the predicate device, Tina-quant C-Reactive Protein Gen 3 on cobas c 501. Analytical equivalence of the test device (y) and the predicate device (x) was evaluated using Passing/Bablok regression analysis. The results are summarized in the following table:

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range(mg/L)</td><td rowspan=1 colspan=1>Equation</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>Pearson r</td></tr><tr><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>3.06-347</td><td rowspan=1 colspan=1>y = 0.985x + 0.278</td><td rowspan=1 colspan=1>0.985(0.97-1.00)</td><td rowspan=1 colspan=1>0.278(0.18-0.40)</td><td rowspan=1 colspan=1>0.999</td></tr></table>

# 2. Matrix Comparison:

The effect on quantitation of analyte in the presence of anticoagulants with the Tina-quant CReactive Protein IV assay was determined by comparing values obtained from samples drawn into serum, serum separation gel, Li-heparin plasma, K2- and K3-EDTA plasma primary tubes. At least 42 serum/plasma pairs per sample type were tested on one cobas c 501 analyzer. Analytical comparison between the results obtained from serum separation gel and each plasma sample type (y) and the results from serum (x) was evaluated using the Passing/Bablok regression analyses. The results are summarized in the following table:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range(mg/L)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>Pearson r</td></tr><tr><td rowspan=1 colspan=1>Serum Separation Gelvs. Serum</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>3.34344</td><td rowspan=1 colspan=1>0.985(0.98-1.00)</td><td rowspan=1 colspan=1>0. 134(-0.070.47)</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>Li-heparin vs. Serum</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>3.34344</td><td rowspan=1 colspan=1>1.029(1.021.04)</td><td rowspan=1 colspan=1>-0.192(-0.36- -0.01)</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>K2-EDTA vs. Serum</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>3.34344</td><td rowspan=1 colspan=1>1.024(1.01-1.04)</td><td rowspan=1 colspan=1>-0.201(-0.480.21)</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>K3-EDTA vs. Serum</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>3.34344</td><td rowspan=1 colspan=1>1.024(1.011.04)</td><td rowspan=1 colspan=1>-0.258(-0.49--0.10)</td><td rowspan=1 colspan=1>0.999</td></tr></table>

# C Clinical Studies:

1. Clinical Sensitivity and Clinical Specificity: Not applicable

2. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable

# D Clinical Cut-Off

See expected values/reference range.

# E Expected Values/Reference Range:

The reference interval was verified by testing samples from 500 healthy adult donors. 467 of 500 samples tested had concentrations ${ < } 5 \mathrm { m g / L }$ .

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.